Why the study?
High sympathetic nerve activity is a cardiovascular risk factor linked to high testosterone, but its role in polycystic ovarian syndrome and the effect of oral contraceptives on it remain unclear.
Does oral contraceptive therapy alter sympathetic nerve activity in women with polycystic ovary syndrome?
Case-Control
Does oral contraceptive therapy alter sympathetic nerve activity in women with polycystic ovary syndrome?
Oral contraceptive use for 1 month significantly improved hormonal and clinical markers of PCOS, though differences in sympathetic nerve activity compared to controls were not statistically significant.
Sympathetic measures did not differ significantly in PCOS; leaves open whether oral contraceptives alter autonomic function.
OBJECTIVE: High sympathetic nerve activity, is thought to be a cardiovascular risk factor, has been shown to correlate with circulating high testosterone levels. However its role on the pathophysiology of the polycystic ovarian syndrome has not been clearly established. The aim of our study is to compare the sympathetic nerve activity between polycystic ovarian syndrome and control group and to determine whether the use of oral contraceptives for contraception has any effect on this activity. MATERIALS AND METHODS: Our study has designed as a prospective, case-control study including patients diagnosed with polycystic ovarian syndrome. Antropometric measurements were calculated, hormone levels were measured and sympathetic skin response and heart rate variability measurements were performed in the laboratory to assess sympathetic activity before starting oral contraceptive pill therapy and at the end of 1 month follow up. RESULTS: In the baseline condition LH/FSH ratio, LH, DHEAS, and total testosterone levels were significantly higher in women with PCOS. After 1 month of treatment, reductions in Ferriman-Gallwey score, ovarian volumes, number of follicles, LH/FSH ratio, LH, and androgen hormone levels were statistically significant. The mean values of sympathetic skin response amplitude and R-R analysis-Valsalva test were higher in PCOS group as compared to the control group. However, these differences were not statistically significant. Similarly, no statistically significant difference in SSR latency and R-R analysis-standup test were demonstrated between PCOS and control groups. CONCLUSION: In conclusion, our study supports the increased sympatovagal activity in patients with polycystic ovarian syndrome.
No takes yet. Share an insight, caveat, or question.
Okyay et al. (2022) conducted a case-control in Polycystic ovarian syndrome. Oral contraceptive pill therapy vs. Control group was evaluated on Sympathetic skin response and heart rate variability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: